Gemtuzumab ozogamicin for untreated de novo CD33-positive acute myeloid leukaemia

Published on 31 Aug 2022
Last Updated on 31 Aug 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Gemtuzumab ozogamicin 5 mg powder for concentrate for solution for infusion in combination with daunorubicin and cytarabine for patients with previously untreated de novo CD33-positive acute myeloid leukaemia (AML), if they:

  • do not have acute promyelocytic leukaemia;

  • only start induction therapy while waiting for cytogenetic test results or after confirming favourable, intermediate or unknown (due to inconclusive test results) cytogenetic risk, and

  • start consolidation therapy after confirming favourable, intermediate, or unknown cytogenetic risk.

Funding status

Gemtuzumab ozogamicin 5 mg powder for concentrate for solution for infusion is recommended for inclusion on the Cancer Drug List (Medication Assistance Fund and MediShield Life monthly claim limit of SG$3200) for the abovementioned indication from 1 September 2022.

Gemtuzumab ozogamicin for untreated de novo CD33+ acute myeloid leukaemia (31 Aug 22) [PDF, 128 KB]

Gemtuzumab ozogamicin for treating de novo CD33+ acute myeloid leukaemia-PES (31 Aug 22) [PDF, 139 KB]